Stock PRME PRIME MEDICINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Prime Medicine, Inc.

Equities

PRME

US74168J1016

Market Closed - Nasdaq
Other stock markets
 21:00:00 20/05/2024 BST 		5-day change 1st Jan Change
7.53 USD +6.36% Intraday chart for Prime Medicine, Inc. +17.29% -15.01%
05-20 HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target MT
05-17 North American Morning Briefing : The "Everything -2- DJ

Evolution of the average Target Price on Prime Medicine, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5db6e0.xX3FgLEAl4IipnyV3RL7mAsm32csWyQ8HlZZA6_4ocE.kDyT8fx3xLpH8iTctVaY9nxXsBZaKFJRaiABM-yQ25XoP5zXwEHQzkv0MQ~3f5644e6f9ac86adbf609edb6f8f3e01

Analyst Recommendations on Prime Medicine, Inc.

HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target MT
Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target MT
JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating MT
Chardan Initiates Prime Medicine With Buy Rating, Price Target is $17 MT
Chardan Initiates Prime Medicine at Buy With $17 Price Target MT
Wedbush Initiates Prime Medicine With Outperform Rating, $12 PT; Notes Positive Long-Term Outlook on Gene Editing Platform MT
Guggenheim Cuts Prime Medicine's Price Target to $20 From $24, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on Prime Medicine to $12 From $18, Keeps Equalweight Rating MT
BMO Capital Starts Prime Medicine at Outperform, $19 Price Target MT
Jones Trading Starts Prime Medicine at Buy With $20 Price Target MT
Morgan Stanley Adjusts Price Target on Prime Medicine to $19 From $21, Keeps Equalweight Rating MT
Guggenheim Starts Prime Medicine at Buy With $24 Price Target MT
Stifel Initiates Prime Medicine at Hold With $18 Price Target MT
Morgan Stanley Adjusts Price Target on Prime Medicine to $21 From $23, Maintains Equal-Weight Rating MT
Goldman Sachs Starts Prime Medicine at Neutral With $22 Price Target MT
JPMorgan Starts Prime Medicine at Overweight With $27 Price Target MT
Jefferies Starts Prime Medicine at Buy With $25 Price Target MT
Morgan Stanley Starts Prime Medicine at Equalweight With $23 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
7.53 USD
Average target price
14.18 USD
Spread / Average Target
+88.34%
High Price Target
20 USD
Spread / Highest target
+165.60%
Low Price Target
9 USD
Spread / Lowest Target
+19.52%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Prime Medicine, Inc.

HC Wainwright
Citigroup
JPMorgan Chase
Chardan Research
Wedbush
Guggenheim
Morgan Stanley
BMO Capital
JonesTrading Institutional Services
Stifel Nicolaus
Jefferies & Co.
Goldman Sachs

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PRME Stock
  4. Consensus Prime Medicine, Inc.